Advancing Survodutide: Exploring the Dual Agonist’s Phase III Potential in Obesity Treatment
Time: 8:30 am
day: Conference Day One
Details:
- Exploring the promising Phase II results of survodutide, which demonstrated up to 19% weight loss in individuals with overweight or obesity
- Gain insights into the design and objectives of the upcoming global Phase III studies, focusing on the efficacy and safety of survodutide in a broader population
- Explore the potential of survodutide’s dual glucagon/GLP-1 receptor agonism to address unmet medical needs in obesity and its associated complications, potentially transforming the treatment landscape
